Featured 13F manager
Alphabet Inc.
Mountain View, CA 4 processed 13Fs on this site · 2025 Q3–2026 Q2
- $99.1B
- 28 Positions
- 2026 Q2
- +2367.2% QoQ
- Top 5 98.5%
Alphabet Inc. files a Form 13F. The latest book is 2026 Q2 at $99.1B, up 2367.2% QoQ, led by Space Exploration ·, Planet Labs Pbc, and Ast Spacemobile.
Portfolio
top 5 98.5% · top 10 99.5%
- SPCX - Space Exploration · CLASS A 95.0%
- PL - Planet Labs Pbc · CL A 1.2%
- ASTS - Ast Spacemobile · CL A 0.8%
- CME - CME Group 0.8%
- ARM — 0.7%
- RVMD - Revolution Medicines 0.5%
- Freshworks · CLASS A 0.2%
- PBLS - Parabilis Medicines 0.1%
- TEM - Tempus Ai · CL A 0.1%
- GTLB - Gitlab · CLASS A 0.1%
- PATH - Uipath · CL A 0.1%
- LIFE - Ethos Technologies · CL A 0.1%
- Other 0.3%
AUM over time
Book
| ASTS - Ast Spacemobile · CL A | 25.18% | Hold | 8,943,486 | $72.63 | $650M | — | — |
| PL - Planet Labs Pbc · CL A | 24.42% | Hold | 31,942,641 | $19.72 | $630M | — | — |
| RVMD - Revolution Medicines | 10.33% | Reduce −19.1% | 3,345,102 | $79.65 | $266M | −788,175 | +$73M |
| ARM — | 8.31% | Hold | 1,960,784 | $109.31 | $214M | — | — |
| Freshworks · CLASS A | 7.70% | Hold | 16,206,643 | $12.25 | $199M | — | — |
| PATH - Uipath · CL A | 4.47% | Hold | 7,034,337 | $16.39 | $115M | — | — |
| GTLB - Gitlab · CLASS A | 3.96% | Hold | 2,724,712 | $37.53 | $102M | — | — |
| TEM - Tempus Ai · CL A | 3.55% | Hold | 1,551,102 | $59.05 | $92M | — | — |
| DXCM - Dexcom | 2.67% | Hold | 1,036,937 | $66.37 | $69M | — | — |
| MAZE - Maze Therapeutics | 2.23% | Reduce −42.4% | 1,388,583 | $41.43 | $58M | −1,023,888 | −$5M |
| PRME - Prime Medicine | 2.23% | Hold | 16,562,498 | $3.47 | $57M | — | — |
| BBOT — | 1.37% | Hold | 2,823,126 | $12.52 | $35M | — | — |
| Relay Therapeutics | 0.51% | Hold | 1,568,753 | $8.46 | $13M | — | — |
| Vera Therapeutics · CL A | 0.47% | Hold | 241,264 | $50.64 | $12M | — | — |
| GLUE - Monte Rosa Therapeutics | 0.45% | Reduce −49.1% | 744,948 | $15.68 | $12M | −719,067 | +$832K |
| Sana Biotechnology | 0.44% | Hold | 2,812,500 | $4.07 | $11M | — | — |
| LYEL - Lyell Immunopharma | 0.35% | Hold | 293,256 | $30.78 | $9M | — | — |
| BEAM - Beam Therapeutics | 0.35% | Hold | 321,604 | $27.72 | $9M | — | — |
| FIG - Figma · CLASS A | 0.31% | Hold | 215,582 | $37.37 | $8M | — | — |
| OSCR - Oscar Health · CL A | 0.27% | Hold | 481,988 | $14.37 | $7M | — | — |
| WGS - Genedx | 0.11% | Hold | 22,711 | $130.06 | $3M | — | — |
| Exact Sciences | 0.09% | Hold | 23,205 | $101.56 | $2M | — | — |
| Spero Therapeutics | 0.08% | Hold | 889,979 | $2.33 | $2M | — | — |
| AUTL - Autolus Therapeutics | 0.05% | Hold | 698,262 | $1.99 | $1M | — | — |
| Hyperfine · CL A | 0.03% | Hold | 898,720 | $0.9800 | $881K | — | — |
| Tenaya Therapeutics | 0.03% | Hold | 915,705 | $0.7100 | $650K | — | — |
| Quince Therapeutics | 0.02% | Hold | 189,122 | $3.35 | $634K | — | — |
| FULC - Fulcrum Therapeutics | 0.01% | Hold | 14,262 | $11.31 | $161K | — | — |
| RGEN - Repligen | 0.00% | Hold | 383 | $163.86 | $63K | — | — |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2025 Q3
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Metsera | 8.22% | Exit | 0 | $52.33 | $198M | −3,783,528 | −$198M |
| DNTH - Dianthus Therapeutics | 0.34% | Exit | 0 | $39.35 | $8M | −208,697 | −$8M |
| FHTX - Foghorn Therapeutics | 0.10% | Exit | 0 | $4.89 | $2M | −500,901 | −$2M |
| TSHA - Taysha Gene Therapies | 0.09% | Exit | 0 | $3.27 | $2M | −640,882 | −$2M |
| Tscan Therapeutics | 0.08% | Exit | 0 | $1.82 | $2M | −1,077,080 | −$2M |
| Holding | 0.08% | Exit | 0 | $1.25 | $2M | −1,513,644 | −$2M |
| GUTS - Fractyl Health | 0.04% | Exit | 0 | $1.59 | $1M | −662,584 | −$1M |
| ALEC - Alector | 0.02% | Exit | 0 | $2.96 | $521K | −175,866 | −$521K |
Filings history
4 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 28 | $99.1B | +2367.2% | 13F-HR | 8/7/2026 | 000165204426000073 |
| 2026 Q1 | 26 | $4B | +55.7% | 13F-HR | 5/8/2026 | 000165204426000051 |
| 2025 Q4 | 29 | $2.6B | +7.1% | 13F-HR | 2/13/2026 | 000165204426000023 |
| 2025 Q3 | 37 | $2.4B | — | 13F-HR | 11/7/2025 | 000165204425000096 |
About
Alphabet Inc.
4 processed 13Fs on this site · 2025 Q3–2026 Q2